Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.

Khunti K, Chen H, Cid-Ruzafa J, Fenici P, Gomes MB, Hammar N, Ji L, Kosiborod M, Pocock S, Shestakova MV, Shimomura I, Tang F, Watada H, Nicolucci A; DISCOVER investigators.

Diabetes Obes Metab. 2020 Jan;22(1):66-78. doi: 10.1111/dom.13866. Epub 2019 Oct 1.

2.

Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication.

Cid Ruzafa J, Ulrichsen SP, Bennett D, Ehrenstein V.

Drugs Real World Outcomes. 2019 Sep;6(3):133-140. doi: 10.1007/s40801-019-0160-6.

3.

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme.

Nicolucci A, Charbonnel B, Gomes MB, Khunti K, Kosiborod M, Shestakova MV, Shimomura I, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Pocock S.

Diabetes Obes Metab. 2019 Nov;21(11):2474-2485. doi: 10.1111/dom.13830. Epub 2019 Aug 5.

4.

Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study.

Gomes MB, Rathmann W, Charbonnel B, Khunti K, Kosiborod M, Nicolucci A, Pocock SJ, Shestakova MV, Shimomura I, Tang F, Watada H, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Ji L; DISCOVER investigators.

Diabetes Res Clin Pract. 2019 May;151:20-32. doi: 10.1016/j.diabres.2019.03.024. Epub 2019 Mar 20.

5.

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).

Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Watada H, Shimomura I, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Khunti K; DISCOVER investigators.

Cardiovasc Diabetol. 2018 Nov 28;17(1):150. doi: 10.1186/s12933-018-0787-8.

6.

An analysis of characteristics of post-authorisation studies registered on the ENCePP EU PAS Register.

Carroll R, Ramagopalan SV, Cid-Ruzafa J, Lambrelli D, McDonald L.

Version 2. F1000Res. 2017 Aug 14 [revised 2017 Jan 1];6:1447. doi: 10.12688/f1000research.12198.2. eCollection 2017.

7.

Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.

Khunti K, Godec TR, Medina J, Garcia-Alvarez L, Hiller J, Gomes MB, Cid-Ruzafa J, Charbonnel B, Fenici P, Hammar N, Hashigami K, Kosiborod M, Nicolucci A, Shestakova MV, Ji L, Pocock S.

Diabetes Obes Metab. 2018 Feb;20(2):389-399. doi: 10.1111/dom.13083. Epub 2017 Sep 28.

8.

Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model.

Cid Ruzafa J, Merinopoulou E, Baggaley RF, Leighton P, Werther W, Felici D, Cox A.

Pharmacoepidemiol Drug Saf. 2016 Aug;25(8):871-9. doi: 10.1002/pds.3927. Epub 2016 Jan 19.

9.

Estimated glomerular filtration rate progression in UK primary care patients with type 2 diabetes and diabetic kidney disease: a retrospective cohort study.

Cid Ruzafa J, Paczkowski R, Boye KS, Di Tanna GL, Sheetz MJ, Donaldson R, Breyer MD, Neasham D, Voelker JR.

Int J Clin Pract. 2015 Aug;69(8):871-82. doi: 10.1111/ijcp.12640. Epub 2015 May 25.

PMID:
26011029
10.

An Epidemiologic Modeling Application To Pharmacoeconomics for Improved Health Care Planning.

Cid RJ, Cox A, Merinopoulou E, Baggaley R, Leighton P, Desai K.

Value Health. 2014 Nov;17(7):A587. doi: 10.1016/j.jval.2014.08.2004. Epub 2014 Oct 26. No abstract available.

11.

Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model.

Starczewska Amelio JM, Cid Ruzafa J, Desai K, Tzivelekis S, Muston D, Khalid JM, Ashman P, Maguire A.

BMC Cancer. 2014 May 24;14:364. doi: 10.1186/1471-2407-14-364. Review.

12.

Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.

Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D.

Eur Respir Rev. 2012 Dec 1;21(126):355-61. doi: 10.1183/09059180.00002512. Review.

13.

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

Cummings KJ, Lee SM, West ES, Cid-Ruzafa J, Fein SG, Aoki Y, Sulkowski MS, Goodman SN.

JAMA. 2001 Jan 10;285(2):193-9. Review.

PMID:
11176813
14.

[Towards evidence-based public health?].

Cid Ruzafa J, Rodríguez Artalejo F, Martín Moreno JM.

Med Clin (Barc). 1999;112 Suppl 1:106-10. Review. Spanish.

PMID:
10618808
15.

Nutrient intakes and adequacy among an older population on the eastern shore of Maryland: the Salisbury Eye Evaluation.

Cid-Ruzafa J, Caulfield LE, Barrón Y, West SK.

J Am Diet Assoc. 1999 May;99(5):564-71.

PMID:
10333778
16.

Anthropometric status and cataract: the Salisbury Eye Evaluation project.

Caulfield LE, West SK, Barrón Y, Cid-Ruzafa J.

Am J Clin Nutr. 1999 Feb;69(2):237-42.

PMID:
9989686
17.

Drug and alcohol use in Spain: consumption habits, attitudes and opinions.

Royo-Bordonada MA, Cid-Ruzafa J, Martin-Moreno JM, Guallar E.

Public Health. 1997 Sep;111(5):277-84.

PMID:
9308374
18.

[Disability evaluation: Barthel's index].

Cid-Ruzafa J, Damián-Moreno J.

Rev Esp Salud Publica. 1997 Mar-Apr;71(2):127-37. Spanish. Erratum in: Rev Esp Salud Publica 1997 Jul-Aug;71(4):411.

Supplemental Content

Loading ...
Support Center